Regeneron Pharmaceuticals Inc. buy Royal Bank of Canada
Summary
This prediction is currently active. The prediction currently has a performance of 11.66%. This prediction currently runs until 09.04.25. The prediction end date can be changed by Royal_Bank_of_Canada at any time. Royal_Bank_of_Canada has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
Name | 1w | 1m |
---|---|---|
Regeneron Pharmaceuticals Inc. | -1.048% | -1.048% |
iShares Core DAX® | -0.543% | 1.491% |
iShares Nasdaq 100 | -2.696% | -1.235% |
iShares Nikkei 225® | -2.863% | 2.491% |
iShares S&P 500 | -1.105% | 0.013% |
Comments by Royal_Bank_of_Canada for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Stopped prediction by Royal_Bank_of_Canada for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
24.06.24
24.06.25
21:35
Regeneron Pharmaceuticals Inc.
12.06.24
12.06.25
21:35
Regeneron Pharmaceuticals Inc.
04.06.24
04.06.25
21:35
Regeneron Pharmaceuticals Inc.
27.02.24
27.02.25
21:35
Regeneron Pharmaceuticals Inc.
05.02.24
05.02.25
21:35
Regeneron Pharmaceuticals Inc.
29.01.24
29.01.25
21:35
Regeneron Pharmaceuticals Inc.
12.01.24
12.01.25
21:35